The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Deion Sanders could be sticking around Boulder for at least a few more years after the University of Colorado head football ...

Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) said March 28 it will exclusively license its drug candidate LX9581 to Danish ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

According to shoppers, one of Costco's best items is their Kirkland Signature Extra Virgin Olive Oil, "particularly the ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Savara (SVRA – Research Report) and Zentalis Pharmaceuticals ...

Johnson & Johnson has been in a holding pattern, posting a small return of 0.7% while floating around $163.19. Does this ...

We believe the new German government’s infrastructure plans have the potential to materially benefit the European high yield ...

From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea.

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Halifax Group ("Halifax"), a middle market private equity firm that partners with management to invest in market-leading ...

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...